Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Acorda Therapeutics (ACOR)

Acorda Therapeutics (ACOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Acorda: Q1 Earnings Snapshot

Acorda: Q1 Earnings Snapshot

ACOR : 0.6610 (-24.86%)
Acorda: Q3 Earnings Snapshot

Acorda: Q3 Earnings Snapshot

ACOR : 0.6610 (-24.86%)
Acorda: Q2 Earnings Snapshot

Acorda: Q2 Earnings Snapshot

ACOR : 0.6610 (-24.86%)
Acorda: Q1 Earnings Snapshot

Acorda: Q1 Earnings Snapshot

ACOR : 0.6610 (-24.86%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.084 (+2.44%)
SILO : 0.9220 (-2.91%)
LLY : 782.35 (-1.72%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.6300 (+2.52%)
IMRN : 2.20 (-1.79%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 0.9220 (-2.91%)
LLY : 782.35 (-1.72%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.6300 (+2.52%)
IMRN : 2.20 (-1.79%)
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in China. INBRIJA...

ACOR : 0.6610 (-24.86%)
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its first quarter 2023 update and financial results on Thursday, May 11 at 4:30 p.m. ET.

ACOR : 0.6610 (-24.86%)
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data on INBRIJA (levodopa inhalation powder) and OFF Periods at the American Academy of Neurology (AAN) Annual Meeting, taking...

ACOR : 0.6610 (-24.86%)
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched an INBRIJA ® (levodopa inhalation powder) television commercial for Parkinson’s Awareness Month.

ACOR : 0.6610 (-24.86%)

Barchart Exclusives

1 Dividend Stock to Snag for Robust Free Cash Flows
This gold miner just made a game-changing acquisition that could boost its free cash flow, making its dividend-paying stock a top pick for investors eyeing big returns. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar